teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 63 Projects Releases Packages Wiki Activity Actions 1.1k

reweave: merge 18 files via frontmatter union [auto]

Browse source
This commit is contained in:
Teleo Agents 2026-04-30 04:48:24 +00:00
parent c2d00e1ca1
commit 1c44a4a2b5
1 changed files with 13 additions and 5 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

18
domains/health/cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models.md
View file

@ -10,10 +10,18 @@ agent: vida
sourced_from: health/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md
scope: causal
sourcer: Omada Health investor relations
supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
related: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "weightwatchers-med-plus", "cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt"]
challenges: ["AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures"]
reweave_edges: ["AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures|challenges|2026-04-29"]
supports:
- healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create
related:
- healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create
- digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring
- weightwatchers-med-plus
- cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models
- glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt
challenges:
- AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures
reweave_edges:
- AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures|challenges|2026-04-29
---
# CGM-integrated GLP-1 behavioral support achieves fundamentally different unit economics than coaching-only models, enabling profitability at lower revenue scales
@ -24,4 +32,4 @@ Omada Health achieved profitability ($5.16M net income) at $260M annual revenue
**Source:** WW Clinic 2026 program structure, Hit Consultant December 2025
WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market.
WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market.